A new study compared the effectiveness of weight-loss drugs tirzepatide and semaglutide, finding tirzepatide leads to greater weight loss and waist reduction. Doctors shared insights.

New animal research being presented at this year’s European Congress on Obesity (ECO) in Malaga, Spain (11-14 May), reveals distinct metabolic adjustments to tirzepatide and semaglutide ...

A new study looked at the effect of semaglutide vs. tirzepatide on weight loss over a 72 week period. At the end of the 72 weeks, people who took tirzepatide lost an average of 50 pounds. Here's ...

A three-year study of tirzepatide – a medication approved in the US as Mounjaro for diabetes and Zepbound for weight loss – found that when adults who had prediabetes and obesity or overweight ...

The study, which involved more than 1,000 prediabetic patients, found that those taking the highest dose of 15 mg lost 23% of their body weight, while those on a placebo lost just 2%. Tirzepatide is ...

Tirzepatide and semaglutide are ... current findings align with results reported in the SURMOUNT 14,18–20 and STEP trials 21 as well as in a recent cohort study that showed greater weight ...

The study found that participants receiving tirzepatide experienced significantly greater weight loss compared to the placebo group. Importantly, the reduction in sleeping metabolic rate and 24-hour ...

Drug manufacturer Eli Lilly announced the results from a three-year study that found its drug tirzepatide slashed the risk of developing type 2 diabetes by 94% in adults with prediabetes who also ...

Tirzepatide therapy has resulted in significant weight reduction, glycemic control, and improvements in other metabolic measures in persons with obesity with or without type 2 diabetes. 13,14 In ...